Silexion’s Cancer Trial Push Puts Focus on Cash

Silexion Therapeutics Corp is pushing its top pancreatic cancer drug toward a mid-to-late-stage trial in people, getting nearer to a key clinical test as its cash runway gets tighter. The small biotech is listed on Nasdaq.